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Abstract
Background: Evidence is necessary but not sufficient for decision-making, such as making recommendations by
clinical practice guideline panels. However, the fundamental premise of evidence-based medicine (EBM) rests on
the assumed link between the quality of evidence and "truth" and/or correctness in making guideline
recommendations. If this assumption is accurate, then the quality of evidence ought to play a key role in making
guideline recommendations. Surprisingly, and despite the widespread penetration of EBM in health care, there has
been no empirical research to date investigating the impact of quality of evidence on the strength of
recommendations made by guidelines panels.
Methods: The American Association of Blood Banking (AABB) has recently convened a 12 member panel to
develop clinical practice guidelines (CPG) for the use of fresh-frozen plasma (FFP) for 6 different clinical
indications. The panel was instructed that 4 factors should play a role in making recommendation: quality of
evidence, uncertainty about the balance between desirable (benefits) and undesirable effects (harms), uncertainty
or variability in values and preferences, and uncertainty about whether the intervention represents a wise use of
resources (costs). Each member of the panel was asked to make his/her final judgments on the strength of
recommendation and the overall quality of the body of evidence. "Voting" was anonymous and was based on the
use of GRADE (Grading quality of evidence and strength of recommendations) system, which clearly distinguishes
between quality of evidence and strength of recommendations.
Results: Despite the fact that many factors play role in formulating CPG recommendations, we show that when
the quality of evidence is higher, the probability of making a strong recommendation for or against an intervention
dramatically increases. Probability of making strong recommendation was 62% when evidence is "moderate",
while it was only 23% and 13% when evidence was "low" or "very low", respectively.
Conclusion: We report the first empirical evaluation of the relationship between quality of evidence pertinent
to a clinical question and strength of the corresponding guideline recommendations. Understanding the
relationship between quality of evidence and probability of making (strong) recommendation has profound
implications for the science of quality measurement in health care.
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Background
Evidence is necessary but not sufficient for decision-mak-
ing, such as making recommendations by clinical practice
guideline (CPG) panels [1]. Indeed, GRADE, a new
emerging system for developing CPG recommendations
clearly distinguishes between quality of evidence (the
extent to which our confidence in an estimate of effect is
correct, i.e. represents the "truth") and strength of recom-
mendations (the extent to which confidence in an esti-
mate of the effect is adequate to support
recommendations, i.e. belief that adherence to a particu-
lar recommendation will do more good than harm)[2].
The GRADE system that has been developed by the pio-
neers of evidence-based medicine (EBM) represents the
major solidification of the entire EBM movement, which,
at its center piece, has always focused on the issues of
(quality of) evidence and decision-making (guidelines
recommendations). In fact, it can be argued that the fun-
daments of EBM rest on the assumed link between the
quality of evidence and "truth" and/or correctness in mak-
ing recommendations for practitioners and patients
alike[3]. If this assumption is an accurate one, then the
quality of evidence ought to play a key role in making
guidelines recommendations. Surprisingly, and despite
the fact that opinion leaders concluded that EBM repre-
sents one of the most important medical milestone of the
last 160 years, in the same category of innovations such as
antibiotics and anesthesia[4], no empirical research to
date has investigated the impact of quality of evidence on
strength of recommendations made by CPG panels. Here,
we report such a study.
Methods
The American Association of Blood Banking (AABB) has
recently convened a panel to develop CPG for the use of
fresh-frozen plasma (FFP) for 6 different clinical indica-
tions (manuscripts in preparation). The panel decided to
employ the GRADE method[2,5] to develop guidelines
for 6 clinical indications regarding the use of FFP. The
panel was composed of 17 members; 11 were representa-
tives of the AABB Clinical Transfusion Medicine Commit-
tee, while 6 were representatives of other professional
organizations including the American Association for the
Study of Liver Disease (AASLD), the American Academy of
Pediatrics (AAP), the American Society of Anesthesiolo-
gists (ASA), the American Society for Hematology (ASH),
and the military. Nine of the members were pathologists
and/or hematologists, two were anesthesiologists, three
were internists, two were pediatricians, and one was a
hepatologist. The panel was aided by three methodolo-
gists: two who performed the systematic review and one
who moderated and assisted the panel in their delibera-
tions. None of the methodologists had "voting" power.
The panel met in person once during a whole day meeting
where the principles of the GRADE methods were intro-
duced and discussed. The panel subsequently had 3 more
conference calls to discuss the evidence and formulate the
guidelines (see below).
GRADE's fundamental premise is that the CPG should be
based on systematic review (SR) of evidence, i.e. a SR of
the totality of relevant highest quality research evidence
represents a scientific foundation for development of clin-
ical practice guidelines[5]. The AABB commissioned a SR,
which also included preparation of the GRADE evidence
profiles[5] summarizing the effect of FFP in various clini-
cal scenarios. The SR was prepared based on the key clini-
cal questions submitted by members of the guidelines
panel. The evidence profile displayed information on the
effect of FFP in terms of benefits and harms for the most
important clinical outcomes (e.g. death, transfusion-asso-
ciated lung injuries etc). The effects were presented both
in terms of absolute and relative effect measures. Follow-
ing the GRADE method, the profiles also contained infor-
mation on study limitations, (in)consistency,(in)
directness, (im)precision and reporting bias as well as the
magnitude of FFP treatment effect, whether the confound-
ers were accounted for, and whether there was a dose-
response[6] for the use of FFP in given clinical circum-
stances. These are the factors that GRADE recommends for
rating the quality of evidence. For each question/indica-
tion, the evidence profiles were given tentative GRADE
quality criteria for each outcome of importance by the sys-
tematic reviewers (who did not participate in making
guideline recommendations). Each member of the panel
was sent a full copy of the SR along with the GRADE evi-
dence profile.
According to the GRADE system, quality of evidence is
rated as:
• High: Considerable confidence in the estimate of
effect. Future research is unlikely to change the esti-
mate of the health intervention's effect.
￿Moderate: Further research is likely to have an
important impact on confidence in the estimate, and
may change the estimate of the health intervention's
effect.
￿Low: Further research is very likely to have an impor-
tant impact on our confidence in the estimate of effect
and is likely to change the estimate.
￿Very low: Any estimate of effect is very uncertain.
The strength of recommendations (for or against inter-
vention) is graded as strong (indicating judgment that
most well informed people will make the same choice),
weak  (indicating judgment that a majority of wellBMC Health Services Research 2009, 9:120 http://www.biomedcentral.com/1472-6963/9/120
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informed people will make the same choice, but a sub-
stantial minority will not), or uncertain (indicating that
the panel made no specific recommendation for or
against interventions). The panel was instructed that 4 fac-
tors should play a role in making recommendation: qual-
ity of evidence, uncertainty about the balance between
desirable (benefits) and undesirable effects (harms),
uncertainty or variability in values and preferences, and
practice setting/uncertainty about whether the interven-
tion represents a wise use of resources (costs)[7]. That is,
the panel was given clear explanations and specific situa-
tions illustrating how it can, for example, make the strong
recommendation even if the quality of evidence is low.
Thus, the panel was fully aware that making recommen-
dations depends on the 4 different dimensions and that
the quality evidence constitutes only one dimension in
formulating the strength of recommendations.
Each member of the panel was asked to make his/her final
judgments on the strength of recommendation and the
overall quality of the body of evidence. "Voting" was
anonymous and were based on the use of GRADE grids for
formulation of the strength of recommendations([8].
Each member of the panel had 2 weeks time to formulate
his/her judgments on the strength of recommendation
and the quality of supporting evidence.
Statistical analysis
Twelve panel members returned the questionnaire and
assessed the quality of evidence and made recommenda-
tions for the use of FFP for 6 different clinical indications.
We assessed the association between the strength of the
recommendation and the corresponding quality ratings as
given by each member of the panel. The strength of the
recommendations was characterized as "strong" ("for" or
"against"), weak ("for" or "against") and "uncertain".
Quality (as determined by each panel member) was
entered as a categorical outcome ("very low", "low", or
"moderate"; since the quality of evidence was never
judged to be high- see Results-the outcome "high" was not
entered for any panel member for any question). Since
"voting" on separate questions by the same member of
the panel was likely not independent, we employed a hier-
archical, multi-level analysis to analyze the relationship
between quality of evidence and the strength of recom-
mendations.
We analyzed the relationship between quality of evidence
and the strength of recommendations using a propor-
tional odds model (cumulative logistic model), an exten-
sion of logistic regression to handle ordinal response
variables. We assessed model fit using a likelihood ratio
test (comparing versus an intercept-only model). We
asserted that the proportionality of odds assumption was
not violated using the score test. The proportional odds
model treats all observations as independent, but "votes"
on separate questions by the same member of the panel
were likely not independent. We explored whether this
had any effect by fitting models that allow non-independ-
ent observations. Specifically, we fitted a generalized lin-
ear mixed model with a cumulative logistic link function
and the panel member as the clustering variable, and an
additional model using generalized estimating equations.
Because the results from the more complicated models
were identical with these of the aforementioned simple
analysis, we present findings from the ordinal logistic
regression (most parsimonious model). Finally, in explor-
atory analyses we treated the quality ratings given by the
panel members as a continuous variable and extrapolated
what the predicted probabilities for an uncertain, weak or
strong recommendation would be for "high" quality evi-
dence.
All analyses were performed using the gllamm program in
Stata SE 9.2[9] and using Proc GENMODE in SAS. All p-
values are two-tailed and considered significant when less
than 0.05.
Results
Table 1 shows a descriptive analysis portraying a relation-
ship between the quality and strength of recommenda-
tions. In our set of data quality ranked from very low to
moderate (i.e., was never ranked "high"). The majority of
votes clustered in the zone of "very low" evidence and
"uncertain" or "weak" recommendations.
In the cumulative logistic model, the odds ratio for
stronger recommendations (stronger than "uncertain", as
well as stronger than "weak") was 2.06 (95% CI 0.77 to
5.51; p = 0.151) when the quality of evidence was "low"
rather than "very low". The corresponding odds ratio was
11.30 (95%CI 2.62 to 48.68; p = 0.001) when the quality
of the evidence was "moderate" rather than "very low".
Overall, quality was associated with the strength of recom-
mendation beyond chance (p = 0.0027, likelihood ratio
test versus an intercept only model). The assumption of
proportionality of odds was not violated (Score test: Chi-
square = 10.5613, p = 0.1029).
To facilitate the interpretation of these results, Figure 1
shows the predicted probability (from the cumulative
logistic model) for making "uncertain", "weak", or
"strong" recommendation (for or against the interven-
tion) as a function of quality. It is evident that the proba-
bility for strong recommendation is highest when quality
is "moderate" rather than "very low" or "low". Probability
of making strong recommendation was 62% when evi-
dence was "moderate", while it was only 23% and 13%
when evidence was "low" or "very low", respectively.BMC Health Services Research 2009, 9:120 http://www.biomedcentral.com/1472-6963/9/120
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Table 1: A relationship between the quality (columns) and strength of recommendations (row): a descriptive analysis*
Strength of Recommendations Quality of Evidence Total
Very low Low Moderate
Uncertain 17 3 0 20
Weak
(for or against intervention)
14 17 4 35
Strong
(for or against intervention)
83 6 1 7
Total 39 23 10 72
* the number represent the votes by 12 members of the panel for 6 different clinical indications
A relationship between the quality of evidence (X axis) and probability of making uncertain, weak or strong recommendation Figure 1
A relationship between the quality of evidence (X axis) and probability of making uncertain, weak or strong 
recommendation. The actual (observed) number of votes is depicted in red in the upper part of the graph.BMC Health Services Research 2009, 9:120 http://www.biomedcentral.com/1472-6963/9/120
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(Additional file 1 displays distribution of the results for
each question).
In exploratory analyses, treating quality as a continuous
variable resulted in qualitatively similar estimates. Extrap-
olating to a hypothetical instance of "high" quality evi-
dence, the predicted probabilities for "strong", "weak" or
"uncertain" recommendation was 77.2, 20.2 or 2.6 per-
cent, respectively.
Discussion
Many factors play a role in making recommendations. As
explained above, the GRADE method, which we used to
develop the FFP transfusion guidelines, stresses the
importance of 4 factors in formulating guideline recom-
mendations: quality of evidence, trade-off between bene-
fits and harms, patient values and preferences, and use of
resources.[7] Nevertheless, our analysis indicates that
when the quality of evidence increases, the probability of
making strong recommendation for or against an inter-
vention dramatically increases. This occurred despite the
fact that the panel members were made aware of all factors
that should be considered in making recommendations.
The quality of evidence had driven the strength of recom-
mendation even in cases of the widespread use of the
intervention in medical practice (e.g. FFP is widely used to
reverse anticoagulation related to intracranial haemor-
rhage, yet the majority of the panel members did not
strongly endorse it, presumably because of low quality of
evidence supporting such a recommendation).
We note with interest that despite the central role that evi-
dence plays in EBM movement, our study is the first
empirical study that researched the role of evidence in
making guidelines recommendations. The only other
study that indirectly investigated a similar issue is one by
Cruse et al[10]. These investigators found that when high-
quality evidence existed, CPG recommendations were the
same regardless which methods were employed in making
the recommendations. In other words, strong scientific
evidence is capable of serving as a neutral, objective arbi-
ter among competing views and helps generate consensus
among parties who, otherwise, may have held the oppo-
site views.[3]
Our study does have some limitations: 1) our study was
based on the example from one guideline only (AABB).
While we believe that the results from studying other
guidelines panels would likely be similar as long these
panels use GRADE method, this conjecture remains to be
confirmed. 2) the panel members' quality assessment
were likely influenced by the quality ratings provided in
the SR originally prepared to facilitate developing guide-
lines recommendations. This quality rating, however, was
related to the quality of evidence for each relevant out-
come that was analyzed in SR. The panel, on the other
hand, rated the quality of the entire body of evidence
across all outcomes. Indeed, the fact that the quality rating
by 12 members of the panel was not uniform for any of 6
recommendations indicates that each member of the
panel was making his/her independent judgments about
the overall quality of evidence; 3) we did not collect data
on other dimensions of importance for making recom-
mendations such as judgments about trade-offs between
benefits and harms, use of resources and patients values
and preferences. Although these factors, particularly judg-
ments on trade-off between benefits and harms and use of
resources have undoubtedly influenced each member's
deliberation, we believe that our results appear to demon-
strate that the quality of evidence is likely to be a key fac-
tor underlying the strength of the panel's
recommendation. 4) due to small sample size (72 obser-
vations) and the lack of data on high-quality evidence, we
could not establish a more accurate relationship between
high quality evidence and strength of recommendations.
For 3 categories of data that are related to the quality of
evidence (very low, low, moderate) and strength of rec-
ommendation (uncertain, weak, strong) our model
assumed a linear relationship. A positive relationship
exists between the quality of evidence (very low, low,
moderate) and strength of recommendation (uncertain,
weak, strong). Score test shows the proportional odds
assumption that cumulative logit model required is satis-
fied. However, if we were to have data on the "high" qual-
ity category, the relationship may change. In fact, decades
of research in psychology and economics show that peo-
ple's perceptions and judgments are not linearly related.
[11]. The same probably applies to making judgments
about recommendations: when quality of evidence is low
or very low, most people are undecided and are reluctant
to endorse a particular intervention. However, when the
quality evidence increases, the threshold to make recom-
mendations is crossed, and the probability of making a
recommendation likely increases in an exponential fash-
ion. This, however, remains to be demonstrated.
Understanding a relationship between quality of evidence
and probability of making (strong) recommendation is
important and has profound implications for the science
of quality measurements in health care. For example, the
GRADE group recommends that adherence to strong rec-
ommendations can be used as a quality criterion or per-
formance indicator.[7] We discussed above 4 factors that
are important for making guidelines recommendations.
All these factors are prone to interpretation and attempt-
ing to derive uniformity of judgments about all 4 factors
is a very difficult exercise. However, as indicated above,
evidence sometimes does succeed in achieving an agree-
ment among rational observers, thus serving as a neutral,
objective arbiter among potentially competing views ofPublish with BioMed Central    and   every 
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the panel members. [3] This typically occurs when evi-
dence is uniformly judged to be high. [10] Under these
circumstances, our analysis suggests that high quality of
evidence would be associated with high probability of
making a strong guideline recommendation, which in
turn can be the basis for a quality criterion or performance
indicator.
Conclusion
The current work provides an empirical demonstration of
the strong link between good quality evidence and deci-
sion-making. Because only strong guideline recommenda-
tions can be used as performance measures or healthcare
quality indicators, it is imperative to design, fund and
conduct pragmatic studies that are resistant to internal
and external biases. This would ideally generate credible
evidence base that will uniformly (close to 100%) be asso-
ciated with strong recommendations. Thus, efforts to
develop performance measures based upon existing
research should focus mainly on areas with good quality
evidence. Additional research is clearly indicated to estab-
lish the true pattern between quality of evidence and
strengths of recommendations.
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